S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
US Dollar Replaced By "Biden Bucks"? (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Most profitable less than $5 stock in the world? (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
US Dollar Replaced By "Biden Bucks"? (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Most profitable less than $5 stock in the world? (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
US Dollar Replaced By "Biden Bucks"? (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Most profitable less than $5 stock in the world? (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
US Dollar Replaced By "Biden Bucks"? (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Most profitable less than $5 stock in the world? (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
NASDAQ:ANIP

ANI Pharmaceuticals - ANIP Stock Forecast, Price & News

$35.39
+0.42 (+1.20%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$34.82
$35.48
50-Day Range
$23.09
$35.39
52-Week Range
$22.31
$60.23
Volume
96,813 shs
Average Volume
71,819 shs
Market Capitalization
$617.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.00

ANI Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
66.7% Upside
$59.00 Price Target
Short Interest
Bearish
7.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.93
Upright™ Environmental Score
News Sentiment
0.43mentions of ANI Pharmaceuticals in the last 14 days
Based on 22 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
226.67%
From $0.75 to $2.45 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

247th out of 1,112 stocks

Pharmaceutical Preparations Industry

119th out of 544 stocks

ANIP stock logo

About ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ANIP shares. StockNews.com upgraded shares of ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday. Raymond James upped their price objective on ANI Pharmaceuticals from $47.00 to $48.00 and gave the stock an "outperform" rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $59.00.

ANI Pharmaceuticals Stock Up 1.2 %

ANIP Stock opened at $35.39 on Friday. ANI Pharmaceuticals has a fifty-two week low of $22.31 and a fifty-two week high of $60.23. The business's 50 day moving average price is $30.33 and its two-hundred day moving average price is $31.82. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.74 and a current ratio of 3.35. The company has a market capitalization of $610.37 million, a price-to-earnings ratio of -8.23 and a beta of 1.05.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Rating) last posted its quarterly earnings results on Monday, August 8th. The specialty pharmaceutical company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.09). ANI Pharmaceuticals had a positive return on equity of 3.68% and a negative net margin of 25.32%. During the same period in the previous year, the company posted $0.49 earnings per share. As a group, analysts forecast that ANI Pharmaceuticals will post 0.75 earnings per share for the current fiscal year.

Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Stock News Headlines

Full-Year 2022 Guidance:
URGENT: Sell these stocks by September 13th
We are weeks away from the biggest stock market event in more than 70 years. Certain stocks and cryptocurrencies could drop by 80%. Bonds and funds could drop even further. Even your social security check could be worth 21% less. Here's how to protect yourself. pixel
ANI Pharmaceuticals Q2 2022 Earnings Preview
URGENT: Sell these stocks by September 13th
We are weeks away from the biggest stock market event in more than 70 years. Certain stocks and cryptocurrencies could drop by 80%. Bonds and funds could drop even further. Even your social security check could be worth 21% less. Here's how to protect yourself. pixel
ANI Pharmaceuticals (ANIP) Scheduled to Post Earnings on Monday
See More Headlines
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Company Calendar

Last Earnings
8/08/2022
Today
8/11/2022
Next Earnings (Estimated)
11/07/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
Employees
601
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$59.00
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+66.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-42,600,000.00
Pretax Margin
-32.90%

Debt

Sales & Book Value

Annual Sales
$216.14 million
Cash Flow
$4.77 per share
Book Value
$17.90 per share

Miscellaneous

Free Float
12,556,000
Market Cap
$617.20 million
Optionable
Optionable
Beta
1.05

Key Executives

  • Mr. Nikhil Lalwani (Age 44)
    Pres, CEO & Director
    Comp: $2.17M
  • Mr. Stephen P. Carey (Age 51)
    CFO, Sr. VP of Fin. & Corp. Sec.
    Comp: $1.11M
  • Mr. James G. Marken (Age 59)
    Sr. VP of Operations & Product Devel.
    Comp: $709.02k
  • Mr. Christopher K. Mutz (Age 50)
    Head of Rare Disease
    Comp: $643.58k
  • Mr. Ori Gutwerg (Age 48)
    Sr. VP of Generics
    Comp: $710.74k
  • Mr. Muthusamy Shanmugam MS R.Ph. (Age 54)
    Head of R&D, COO of Novitium Operations & Director
  • Ms. Meredith W. Cook
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Mr. Chad Gassert (Age 46)
    Sr. VP of Corp. Devel. & Strategy
  • Ms. Elizabeth Powell J.D.
    Chief Compliance Officer & Head of Legal of Rare Disease
  • Dr. Mary Pao M.D.
    Ph.D., Chief Medical Officer of Rare Disease













ANIP Stock - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings
or view top-rated stocks.

What is ANI Pharmaceuticals' stock price forecast for 2022?

3 equities research analysts have issued 1-year target prices for ANI Pharmaceuticals' shares. Their ANIP share price forecasts range from $48.00 to $70.00. On average, they expect the company's share price to reach $59.00 in the next twelve months. This suggests a possible upside of 66.7% from the stock's current price.
View analysts price targets for ANIP
or view top-rated stocks among Wall Street analysts.

How have ANIP shares performed in 2022?

ANI Pharmaceuticals' stock was trading at $46.08 at the start of the year. Since then, ANIP stock has decreased by 23.2% and is now trading at $35.39.
View the best growth stocks for 2022 here
.

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our ANIP earnings forecast
.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) posted its earnings results on Monday, August, 8th. The specialty pharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.22 by $0.09. ANI Pharmaceuticals had a positive trailing twelve-month return on equity of 3.68% and a negative net margin of 25.32%. During the same quarter in the prior year, the business posted $0.49 earnings per share.

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of $1.34-$1.62 for the period, compared to the consensus EPS estimate of $1.43. The company issued revenue guidance of $295.00 million-$315.00 million, compared to the consensus revenue estimate of $304.50 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include William Blair Investment Management LLC (3.23%), Emerald Advisers LLC (2.64%), Thompson Siegel & Walmsley LLC (2.53%), Emerald Mutual Fund Advisers Trust (2.07%), Global Alpha Capital Management Ltd. (1.88%) and Kennedy Capital Management Inc. (0.94%). Insiders that own company stock include Jeanne Thoma, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends
.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $35.39.

How much money does ANI Pharmaceuticals make?

ANI Pharmaceuticals (NASDAQ:ANIP) has a market capitalization of $610.37 million and generates $216.14 million in revenue each year. The specialty pharmaceutical company earns $-42,600,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis.

How many employees does ANI Pharmaceuticals have?

The company employs 601 workers across the globe.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The official website for the company is www.anipharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at ir@anipharmaceuticals.com, or via fax at 218-634-3540.

This page (NASDAQ:ANIP) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.